68240-63-1 Usage
General Description
[(4-Methylphenyl)phenylmethyl]piperazine, also known as 4-MPPP, is a chemical compound that belongs to the piperazine class of chemicals. It is a psychoactive drug that acts as a stimulant and empathogen. 4-MPPP is a derivative of piperazine and is closely related to various designer drugs such as 2C-B, MDMA, and amphetamine. The compound is structurally similar to other psychoactive substances and has been reported to produce similar effects, including euphoria, increased energy, and altered perception. 4-MPPP has been sold as a recreational drug and has been identified in various illicit substances. It is considered to be a controlled substance in several countries due to its potential for abuse and dependence.
Check Digit Verification of cas no
The CAS Registry Mumber 68240-63-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,8,2,4 and 0 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 68240-63:
(7*6)+(6*8)+(5*2)+(4*4)+(3*0)+(2*6)+(1*3)=131
131 % 10 = 1
So 68240-63-1 is a valid CAS Registry Number.
InChI:InChI=1/C18H22N2/c1-15-7-9-17(10-8-15)18(16-5-3-2-4-6-16)20-13-11-19-12-14-20/h2-10,18-19H,11-14H2,1H3
68240-63-1Relevant articles and documents
Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors
Pajouhesh, Hassan,Feng, Zhong-Ping,Ding, Yanbing,Zhang, Lingyun,Pajouhesh, Hossein,Morrison, Jerrie-Lynn,Belardetti, Francesco,Tringham, Elizabeth,Simonson, Eric,Vanderah, Todd W.,Porreca, Frank,Zamponi, Gerald W.,Mitscher, Lester A.,Snutch, Terrance P.
scheme or table, p. 1378 - 1383 (2010/07/06)
A novel series of compounds derived from the previously reported N-type calcium channel blocker NP118809 (1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one) is described. Extensive SAR studies resulted in compounds with IC50 values in the range of 10-150 nM and selectivity over the L-type channels up to nearly 1200-fold. Orally administered compounds 5 and 21 exhibited both anti-allodynic and anti-hyperalgesic activity in the spinal nerve ligation model of neuropathic pain.
